MOUNTAIN VIEW, Calif., Dec. 17, 2013 /PRNewswire-iReach/ -- Surpass, Inc. ("Surpass"), a recognized leader in preclinical research, announced today the appointment of Tim Pelura, PhD as Surpass' President and Chief Executive Officer effective on December 16, 2013. Dr. Pelura is a serial life science entrepreneur and executive with more than 35 years of experience in pharmaceutical, biotech and medical device industries and has been pivotal in the development of several new drugs spanning numerous therapeutic areas. His perspective as a preclinical CRO customer and breadth of experience will be instrumental in expanding Surpass' leadership position in the preclinical CRO industry.
"I am pleased to be joining such a motivated team of highly talented individuals. Surpass is a recognized leader in preclinical research and one of only a few CROs with AAALAC accredited facilities in multiple major centers for biomedical research," said Dr. Pelura. "I look forward to building on the established reputation of our company and continuing to grow the business to better serve our customers within the preclinical life sciences community."
Dr. Pelura is a respected business leader with a long successful history of growing small companies within the life sciences space. In his most recent position he served as president of BioEntrep, a strategic consultancy focused on transforming life science technologies into high value, medical products by delivering sound advice and needed capacity in the areas of finance; business, corporate and preclinical development; clinical/regulatory strategy; and corporate communications. Prior to BioEntrep, Dr. Pelura held positions as Chairman, President and CEO of Immunome, an antibody platform company; CEO of Promedior, a product-focused biotech company developing novel therapeutics for the treatment of fibrotic diseases; CSO of Kereos responsible for all R&D activities for their oncology, cardiology, and molecular imaging programs; President and COO of Provasis Therapeutics, a developer of interventional neurosurgical devices; as well as various other roles including executive R&D positions at Neuron Therapeutics, Alliance Pharmaceutical Corp., and Pharmacia.
Dr. Pelura earned his doctorate and master's degrees in Chemistry as well as a bachelor's degree in Biological Sciences from Rutgers University.
A recognized leader in preclinical research, Surpass provides comprehensive services for the development, characterization, and evaluation of medical devices, pharmaceuticals, biologics, and combination products with extensive expertise in surgical and interventional procedures. Experienced professionals, state-of-the-art facilities with advanced equipment, and proven methods make Surpass a trusted partner and lab of choice for preclinical feasibility, product development, pivotal GLP safety, and physician training studies. Whether you are a startup or an established player, Surpass-Silicon Valley, LLC (Northern California) and Surpass, Inc. (Midwest/Twin Cities Area) are uniquely qualified to make your study successful. Contact Surpass today at (651) 433-4277 (Midwest) or (650) 477-8267 / (650) 938-2101 (Northern California).
Visit www.surpassinc.com for more information. Connect with Surpass, Inc. on LinkedIn.
Media Contact: D Forkey, Surpass, Inc., 650-938-2101, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com